Biotechnology company Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) announced on Monday that it has signed a Master Services Agreement with Heureka Labs Inc, marking the launch of a long-term AI-powered partnership in gene therapy research. The agreement, finalised on 11 April 2025, will see Heureka provide access to its proprietary artificial intelligence platform for genomic data analysis.

Heureka's platform, developed as a spin-off from Duke University, specialises in interpreting high-dimensional datasets such as RNA sequencing and gene expression profiles. The integration of this technology is expected to enhance Genflow's ability to optimise therapeutic design and personalise treatment strategies through advanced analysis of gene regulatory networks. Genflow will retain full intellectual property rights under the agreement.

Initial work will focus on GF-1002, Genflow's lead SIRT6-based gene therapy candidate, currently in preclinical development. Applications may extend to pipeline programs, including potential therapies for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Genflow, founded in 2020 and headquartered in the UK, is the only publicly listed longevity company in Europe. The company is advancing gene therapies aimed at decelerating the aging process, with a 12-month proof-of-concept trial of GF-1002 in aged dogs underway since March 2025. A separate trial targeting MASH is planned for later in the year.